PMID-sentid	Pub_year	Sent_text	comp_official_name	comp_offset	protein_name	organism	prot_offset
34606641-5	2021	Importantly, osteoblast/osteocyte-specific Sost gene deletion mirrors the accumulation of PDGFRalpha+ adipoprogenitors, reduction in fat mass, and improved glucose metabolism evident in Sost-/- mice.	Glucose	156-163	sclerostin	Mus musculus	43-47
33767359-8	2021	Kindlin-2-deficient osteocytes express abundant Sclerostin, contributing to bone loss in cKO mice.	CKO	89-92	sclerostin	Mus musculus	48-58
34537437-0	2022	Sclerostin antibody improves phosphate metabolism hormones, bone formation rates, and bone mass in adult Hyp mice.	Phosphates	29-38	sclerostin	Mus musculus	0-10
34537437-4	2022	Our previous study reported that a monoclonal antibody to sclerostin (Scl-Ab) decreases FGF23 and increases phosphate and bone mass in growing Hyp mice (XLH murine model).	scl-ab	70-76	sclerostin	Mus musculus	58-68
34537437-4	2022	Our previous study reported that a monoclonal antibody to sclerostin (Scl-Ab) decreases FGF23 and increases phosphate and bone mass in growing Hyp mice (XLH murine model).	Phosphates	108-117	sclerostin	Mus musculus	58-68
34537437-10	2022	Our study suggests that Scl-Ab treatment can improve several skeletal and metabolic pathologies associated with XLH, further establishes the role of sclerostin in the regulation of FGF23 and provides evidence that Scl-Ab can improve phosphate regulation by targeting the bone-renal axis.	scl-ab	24-30	sclerostin	Mus musculus	149-159
33722775-6	2021	The 8 kb sequence upstream of Sost gene transcription start site possesses multiple PPARG binding elements (PPREs) with at least two of them binding PPARG with dynamics reflecting its activation with full agonist rosiglitazone and correlating with increased levels of Sost transcript and sclerostin protein expression (Pearson"s r = 0.9910, p = 0.001).	Rosiglitazone	213-226	sclerostin	Mus musculus	30-34
34421825-10	2021	In NAFLD subjects, sclerostin was negatively correlated with multiple metabolic parameters, including waist circumference, urea, hepatic enzyme, gamma-glutamyl transpeptidase, and triglyceride, while such correlation was not significant in control subjects.	Urea	123-127	sclerostin	Mus musculus	19-29
34421825-10	2021	In NAFLD subjects, sclerostin was negatively correlated with multiple metabolic parameters, including waist circumference, urea, hepatic enzyme, gamma-glutamyl transpeptidase, and triglyceride, while such correlation was not significant in control subjects.	Triglycerides	180-192	sclerostin	Mus musculus	19-29
35278242-13	2022	Together, suppression of sost/sclerostin or dkk1 each augmented IVD structure by stimulating Wnt signaling, but scl-Ab outperformed dkk1-Ab in strengthening the IVD.	scl-ab	112-118	sclerostin	Mus musculus	30-40
35216216-7	2022	17beta-estradiol prevents the increase of FGF23 by inhibiting JNK and NF-kB activation, osteocyte apoptosis and by the down-regulation of osteoclastogenic factors, such as sclerostin.	Estradiol	0-16	sclerostin	Mus musculus	172-182
35049744-7	2022	A significant outcome of this study is that MLO-Y4 cells, when cultured on a hydroxyapatite (HA)-containing two-dimensional (2D) film analogue, expressed Sost.	Durapatite	77-91	sclerostin	Mus musculus	154-158
35049744-7	2022	A significant outcome of this study is that MLO-Y4 cells, when cultured on a hydroxyapatite (HA)-containing two-dimensional (2D) film analogue, expressed Sost.	Durapatite	93-95	sclerostin	Mus musculus	154-158
33737193-3	2021	Neutralizing antibodies to sclerostin (Scl-Ab) increase bone mass and strength by increasing bone formation and reducing bone resorption.	scl-ab	39-45	sclerostin	Mus musculus	27-37
34502021-4	2021	Our analyses revealed an increased frequency of granulocytes in the BM of Scl-Ab-treated mice and WT Sost-/- chimeras, indicating myeloid-biased differentiation in Sost-deficient BM microenvironments.	scl-ab	74-80	sclerostin	Mus musculus	164-168
35451627-9	2022	Isovitexin inhibited bone and serum sclerostin as well as the serum type I collagen cross-linked C-telopeptide in OVX mice.	isovitexin	0-10	sclerostin	Mus musculus	36-46
35123265-0	2022	Extracellular acidification augments sclerostin and osteoprotegerin production by Ocy454 mouse osteocytes.	ocy454	82-88	sclerostin	Mus musculus	37-47
35123265-4	2022	L- and d-lactic acid with low chiral selectivity and acidification of the medium raised the production of sclerostin and osteoprotegerin by Ocy454 cells.	l- and d-lactic acid	0-20	sclerostin	Mus musculus	106-116
33448319-11	2021	Furthermore, DHA decreased the inhibition of sclerostin through reduction of LIF secretion by osteoclasts and, hence, attenuated aberrant bone remodeling and inhibited angiogenesis in subchondral bone, further reducing the progression of OA.	artenimol	13-16	sclerostin	Mus musculus	45-55
33719588-8	2021	PEMF significantly suppressed osteocytic apoptosis and sclerostin expression in KK-Ay mice.	pemf	0-4	sclerostin	Mus musculus	55-65
33833136-4	2021	Here, we analyzed the conformational dynamics of SOST-LRP6 E1E2 complex using hydrogen/deuterium exchange mass spectrometry (HDX-MS).	Hydrogen	78-86	sclerostin	Mus musculus	49-53
33833136-4	2021	Here, we analyzed the conformational dynamics of SOST-LRP6 E1E2 complex using hydrogen/deuterium exchange mass spectrometry (HDX-MS).	Deuterium	87-96	sclerostin	Mus musculus	49-53
33907818-0	2021	Advanced oxidation protein products aggravate age-related bone loss by increasing sclerostin expression in osteocytes via ROS-dependent downregulation of Sirt1.	Reactive Oxygen Species	122-125	sclerostin	Mus musculus	82-92
33907818-7	2021	The accumulated ROS then upregulated sclerostin expression in MLO-Y4 cells by decreasing Sirt1 expression.	Reactive Oxygen Species	16-19	sclerostin	Mus musculus	37-47
33907818-10	2021	Collectively, these data suggested that AOPPs aggravated age-related bone loss by increasing the expression of sclerostin in osteocytes via ROS-dependent downregulation of Sirt1.	Reactive Oxygen Species	140-143	sclerostin	Mus musculus	111-121
32845528-0	2021	Sclerostin-Neutralizing Antibody Treatment Rescues Negative Effects of Rosiglitazone on Mouse Bone Parameters.	Rosiglitazone	71-84	sclerostin	Mus musculus	0-10
32845528-13	2021	These data suggest targeting sclerostin can prevent rosiglitazone-induced bone loss and reduce BM adiposity, in some, but not all BMAT locations.	Rosiglitazone	52-65	sclerostin	Mus musculus	29-39
30032440-2	2019	We found that, in ultra-high-molecular-weight polyethylene particle-induced osteolysis mouse models, metformin had bone protect property and reduced the negative regulator of bone formation sclerostin (SOST) and Dickkopf-related protein 1 (DKK1), and increased osteoprotegerin (OPG) secretion and the ratio of OPG/Receptor Activator for Nuclear Factor-kappaB Ligand (RANKL).	Metformin	101-110	sclerostin	Mus musculus	202-206
32330695-4	2020	No effect was seen on the osteoclast regulatory genes Rankl and Opg, however the wnt antagonist Sost/sclerostin was potently and dose-dependently downregulated in response to taurine supplementation.	Taurine	175-182	sclerostin	Mus musculus	96-100
32330695-4	2020	No effect was seen on the osteoclast regulatory genes Rankl and Opg, however the wnt antagonist Sost/sclerostin was potently and dose-dependently downregulated in response to taurine supplementation.	Taurine	175-182	sclerostin	Mus musculus	101-111
32330695-8	2020	For the first time, we describe the synthesis of taurine by osteocytes, potentially to preserve viability and to regulate bone formation through inhibition of sclerostin.	Taurine	49-56	sclerostin	Mus musculus	159-169
32156525-6	2020	Cell viability and their capacity to produce receptor activator of nuclear factor kappa-B ligand (RANKL), osteoprotegerin (OPG) and sclerostin (SOST) were detected by MTT and Western blot assays, respectively.	monooxyethylene trimethylolpropane tristearate	167-170	sclerostin	Mus musculus	132-142
32156525-6	2020	Cell viability and their capacity to produce receptor activator of nuclear factor kappa-B ligand (RANKL), osteoprotegerin (OPG) and sclerostin (SOST) were detected by MTT and Western blot assays, respectively.	monooxyethylene trimethylolpropane tristearate	167-170	sclerostin	Mus musculus	144-148
31743490-0	2020	Sclerostin antibody treatment increases bone mass and normalizes circulating phosphate levels in growing Hyp mice.	Phosphates	77-86	sclerostin	Mus musculus	0-10
31743490-8	2020	This short-term treatment study suggests that Scl-Ab treatment can effectively improve some of the pathologies associated with XLH, including normalization of phosphate, and that sclerostin may play a role in regulating FGF23 and phosphate metabolism in XLH.	Phosphates	230-239	sclerostin	Mus musculus	179-189
31828567-5	2020	This heparin binding protein also interacts with other highly sulfated GAGs including, disulfated-dermatan sulfate and chondroitin sulfate E. In addition, liquid chromatography-mass spectrometry was used to characterize the structure of sulfated GAGs that bound to SOST.	Sulfates	62-69	sclerostin	Mus musculus	265-269
31757981-6	2019	IDG-SW3 cells cultured under high glucose conditions displayed significantly increased Sost mRNA(100-fold) and sclerostin protein, a negative regulator of bone formation(5000-fold), compared to cells in control media.	Glucose	34-41	sclerostin	Mus musculus	87-91
31757981-6	2019	IDG-SW3 cells cultured under high glucose conditions displayed significantly increased Sost mRNA(100-fold) and sclerostin protein, a negative regulator of bone formation(5000-fold), compared to cells in control media.	Glucose	34-41	sclerostin	Mus musculus	111-121
30735798-4	2019	In the present study, the effects of AGE2 and Porphyromonas gingivalis lipopolysaccharide (P-LPS) on the expression of sclerostin in mouse osteocyte-like cells (MLO-Y4-A2 cells) and its function in osteoblast differentiation were investigated.	p-lps	91-96	sclerostin	Mus musculus	119-129
30735798-5	2019	AGE2 and P-LPS up-regulated the expressions of receptor of AGE (RAGE) and Toll-like receptor 2 (TLR2), respectively, and significantly up-regulated that of sclerostin and interleukin 6 (IL-6) in osteocytes.	p-lps	9-14	sclerostin	Mus musculus	156-166
30735798-6	2019	Sclerostin, RAGE and TLR2 levels were synergistically increased by AGE2 and P-LPS.	p-lps	76-81	sclerostin	Mus musculus	0-10
30735798-7	2019	The siRNAs of RAGE and TLR2 significantly inhibited AGE2- and P-LPS-induced sclerostin expression.	p-lps	62-67	sclerostin	Mus musculus	76-86
30735798-9	2019	On the other hand, P-LPS elevated sclerostin levels via the TLR2, JNK and p38, and NF-kappaB signal pathways.	p-lps	19-24	sclerostin	Mus musculus	34-44
33339872-2	2020	Pharmacological inhibition of Sost/sclerostin provides a new drug strategy for treating osteoporosis.	sclerostin	35-45	sclerostin	Mus musculus	30-34
32623526-4	2020	Incubation with Ti particles caused apoptosis of MLO-Y4cells.Treatment with Ti particles significantly increased expression of the osteocytic marker SOST/sclerostin.	Titanium	16-18	sclerostin	Mus musculus	149-153
32623526-4	2020	Incubation with Ti particles caused apoptosis of MLO-Y4cells.Treatment with Ti particles significantly increased expression of the osteocytic marker SOST/sclerostin.	Titanium	16-18	sclerostin	Mus musculus	154-164
31793033-8	2020	Gene expression analyses of trabecular and cortical bone showed that PTH (1-34) and abaloparatide led to different actions in osteoblast differentiation and activity, with increased Runx2, Col1A1, Alpl, Bsp, Ocn, Sost, Rankl/Opg and c-fos at different time points.	abaloparatide	84-97	sclerostin	Mus musculus	213-217
32134561-3	2020	We aimed to verify whether the SOST gene was involved in osteolysis induced by titanium (Ti) particles and to investigate the effects of SOST reduction on osteolysis.	Titanium	79-87	sclerostin	Mus musculus	31-35
32134561-11	2020	In summary, our results suggested that reduction of SOST gene can activate the Wnt/beta-catenin signalling pathway, promoting bone formation and compensated for bone loss induced by Ti particles.	Titanium	182-184	sclerostin	Mus musculus	52-56
31082400-7	2019	KEY FINDINGS: FGF-2 abrogated the dexamethasone induced inhibitory effect on osteoblast differentiation by modulating BMP-2 pathway and inhibiting Wnt antagonist sclerostin.	Dexamethasone	34-47	sclerostin	Mus musculus	162-172
31292298-0	2019	Vitamin D-regulated osteocytic sclerostin and BMP2 modulate uremic extraskeletal calcification.	Vitamin D	0-9	sclerostin	Mus musculus	31-41
31292298-7	2019	Our study provides evidence that local osteocytic production of 1,25(OH)2D stimulates sclerostin and inhibits BMP2 production in murine CKD, thus mitigating osteoblastic transdifferentiation and mineralization of soft tissues.	1,25(oh)2d	64-74	sclerostin	Mus musculus	86-96
31292298-8	2019	Increased osteocytic 1,25(OH)2D production, triggered by renal malfunction, may represent a "primary defensive response" to protect the organism from ectopic calcification by increasing sclerostin and suppressing BMP2 production.	(oh)2d	25-31	sclerostin	Mus musculus	186-196
30032440-4	2019	Metformin (50 muM) significantly decreased SOST and DKK1 mRNA expression, stimulating alkaline phosphatase activity and proliferation of osteoblast, and increased OPG secretion and the ratio of OPG/RANKL, inhibiting osteoclastogenesis.	Metformin	0-9	sclerostin	Mus musculus	43-47
29032815-9	2017	Rosiglitazone also induced a greater number of osteoclasts and a greater expression of Sost and Hyou1 at 21 days of lesions.	Rosiglitazone	0-13	sclerostin	Mus musculus	87-91
30590327-0	2019	Regulation of osteoblast differentiation by osteocytes cultured on sclerostin antibody conjugated TiO2 nanotube array.	titanium dioxide	98-102	sclerostin	Mus musculus	67-77
30590327-2	2019	In this study, osteoblasts were co-cultured with osteocytes (MLO-Y4 cells) on the surface of sclerostin antibody-conjugated TiO2 nanotube arrays (TNTs-scl).	titanium dioxide	124-128	sclerostin	Mus musculus	93-103
30590327-3	2019	Field emission scanning electron microscopy (SEM), contact angle measurement and confocal laser scanning microscope (CLSM) were employed to characterize the conjugation of sclerostin antibody onto the surface of TiO2 nanotube arrays.	titanium dioxide	212-216	sclerostin	Mus musculus	172-182
29377313-10	2018	Furthermore, intra-articular administration of recombinant Sost protein, immediately post-injury, also significantly decreased MMP activity levels relative to PBS-treated controls, and Sost activation in response to injury was TNFalpha and NF-kappaB dependent.	Lead	159-162	sclerostin	Mus musculus	59-63
29378325-5	2018	OCP induced the appearance of an alkaline phosphatase (ALP) peak in the IDG-SW3 cells compared to beta-TCP and HA and increased SOST/sclerostin and FGF23 gene expression after 35 days of incubation.	octacalcium phosphate	0-3	sclerostin	Mus musculus	128-132
29378325-5	2018	OCP induced the appearance of an alkaline phosphatase (ALP) peak in the IDG-SW3 cells compared to beta-TCP and HA and increased SOST/sclerostin and FGF23 gene expression after 35 days of incubation.	octacalcium phosphate	0-3	sclerostin	Mus musculus	133-143
29090474-2	2018	Antibodies targeting and neutralizing sclerostin (Scl-Ab) have been shown to increase bone mass and reduce fracture risk.	scl-ab	50-56	sclerostin	Mus musculus	38-48
28601732-11	2017	Further, the intermittent compressive stress reduced Sost mRNA expression and this phenomenon could be rescued by a DAPT pretreatment, implying the involvement of Notch signaling.	dapt	116-120	sclerostin	Mus musculus	53-57
31966426-8	2017	In addition, DMM resulted in significantly greater subchondral bone changes compared with sham surgery in SOST Tg mice at 8 weeks post-surgery.	4,5-dimethylmisonidazole	13-16	sclerostin	Mus musculus	106-110
24876121-5	2014	Clues in this regard have come from the study of humans and mice with inactivating mutations of the sclerostin gene that both have increased skeletal density, which would necessitate an increase in intestinal absorption and/or renal reabsorption of calcium.	Calcium	249-256	sclerostin	Mus musculus	100-110
27683064-2	2017	We demonstrate herein that mice with type 1 DM induced by streptozotocin exhibited low bone mass, inferior mechanical and material properties, increased bone resorption, decreased bone formation, increased apoptosis of osteocytes, and increased expression of the osteocyte-derived bone formation inhibitor Sost/sclerostin.	Streptozocin	58-72	sclerostin	Mus musculus	306-310
25446885-5	2015	Thus, in Sost knockout mice, concentrations of serum 1,25-dihydroxyvitamin D (1,25(OH)2D) are increased and concentrations of FGF-23 are decreased thereby allowing a positive calcium and phosphorus balance.	1,25-dihydroxyvitamin D	53-76	sclerostin	Mus musculus	9-13
25446885-5	2015	Thus, in Sost knockout mice, concentrations of serum 1,25-dihydroxyvitamin D (1,25(OH)2D) are increased and concentrations of FGF-23 are decreased thereby allowing a positive calcium and phosphorus balance.	Calcium	175-182	sclerostin	Mus musculus	9-13
25446885-5	2015	Thus, in Sost knockout mice, concentrations of serum 1,25-dihydroxyvitamin D (1,25(OH)2D) are increased and concentrations of FGF-23 are decreased thereby allowing a positive calcium and phosphorus balance.	Phosphorus	187-197	sclerostin	Mus musculus	9-13
25446885-6	2015	Additionally, in the absence of Sost expression, urinary calcium is decreased, either through a direct effect of sclerostin on renal calcium handling, or through its effect on the synthesis of 1,25(OH)2D.	Calcium	57-64	sclerostin	Mus musculus	113-123
25446885-6	2015	Additionally, in the absence of Sost expression, urinary calcium is decreased, either through a direct effect of sclerostin on renal calcium handling, or through its effect on the synthesis of 1,25(OH)2D.	Calcium	133-140	sclerostin	Mus musculus	113-123
28824162-10	2017	Furthermore, the changes induced by Dex in osteocytes, such as increased SOST, RANKL, and DMP-1 mRNA level and decreased Destrin mRNA level, were reversed by rhPTH (1-34).	Dexamethasone	36-39	sclerostin	Mus musculus	73-77
28062506-10	2017	Incubation of vascular smooth muscle cells with the demethylating agent 5-azacytidine resulted in upregulation of SOST, suggesting that SOST is epigenetically regulated.	Azacitidine	72-85	sclerostin	Mus musculus	114-118
28062506-10	2017	Incubation of vascular smooth muscle cells with the demethylating agent 5-azacytidine resulted in upregulation of SOST, suggesting that SOST is epigenetically regulated.	Azacitidine	72-85	sclerostin	Mus musculus	136-140
27038990-7	2017	More importantly, we show that these cells respond to demethylating treatment, as shown by the increase in SOST mRNA levels, the gene encoding sclerostin, upon treatment of the recipient mice with AzadC.	Decitabine	197-202	sclerostin	Mus musculus	107-111
27038990-7	2017	More importantly, we show that these cells respond to demethylating treatment, as shown by the increase in SOST mRNA levels, the gene encoding sclerostin, upon treatment of the recipient mice with AzadC.	Decitabine	197-202	sclerostin	Mus musculus	143-153
27723935-7	2016	In vivo, intermittent PTH (iPTH)-induced suppression of sclerostin/SOST was accentuated in Dmp1-cre; Cdh2f/f (Cdh2DeltaDmp1 ) mice, compared with Cdh2f/f mice.	ipth	27-31	sclerostin	Mus musculus	56-66
27723935-7	2016	In vivo, intermittent PTH (iPTH)-induced suppression of sclerostin/SOST was accentuated in Dmp1-cre; Cdh2f/f (Cdh2DeltaDmp1 ) mice, compared with Cdh2f/f mice.	ipth	27-31	sclerostin	Mus musculus	67-71
26721590-7	2016	Finally, we propose a model to explain how Scl-Ab can improve the Dmp1 KO osteomalacia phenotype, in which the sclerostin level is already low.	scl-ab	43-49	sclerostin	Mus musculus	111-121
26713363-0	2016	Activation of AMP-activated protein kinase decreases receptor activator of NF-kappaB ligand expression and increases sclerostin expression by inhibiting the mevalonate pathway in osteocytic MLO-Y4 cells.	Mevalonic Acid	157-167	sclerostin	Mus musculus	117-127
26713363-3	2016	RESULTS: Real-time PCR showed that AMPK activation by 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR) significantly decreased the expression of Rankl in a dose- and time-dependent manner and significantly increased the expression of Sost, the gene encoding sclerostin, in osteocytic MLO-Y4 cells.	AICA ribonucleotide	54-99	sclerostin	Mus musculus	239-243
26713363-3	2016	RESULTS: Real-time PCR showed that AMPK activation by 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR) significantly decreased the expression of Rankl in a dose- and time-dependent manner and significantly increased the expression of Sost, the gene encoding sclerostin, in osteocytic MLO-Y4 cells.	AICA ribonucleotide	54-99	sclerostin	Mus musculus	263-273
26713363-3	2016	RESULTS: Real-time PCR showed that AMPK activation by 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR) significantly decreased the expression of Rankl in a dose- and time-dependent manner and significantly increased the expression of Sost, the gene encoding sclerostin, in osteocytic MLO-Y4 cells.	AICA ribonucleotide	101-106	sclerostin	Mus musculus	239-243
26713363-3	2016	RESULTS: Real-time PCR showed that AMPK activation by 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR) significantly decreased the expression of Rankl in a dose- and time-dependent manner and significantly increased the expression of Sost, the gene encoding sclerostin, in osteocytic MLO-Y4 cells.	AICA ribonucleotide	101-106	sclerostin	Mus musculus	263-273
26713363-6	2016	Simvastatin, an inhibitor of HMG-CoA reductase, significantly decreased Rankl expression and increased Sost expression in MLO-Y4 cells.	Simvastatin	0-11	sclerostin	Mus musculus	103-107
26713363-8	2016	CONCLUSION: These findings indicated that AMPK regulated RANKL and sclerostin expression through the mevalonate pathway in osteocytes.	Mevalonic Acid	101-111	sclerostin	Mus musculus	67-77
25952969-10	2016	Additionally, we found sclerostin levels to be elevated in STZ mice and beta-catenin activity to be reduced.	Streptozocin	59-62	sclerostin	Mus musculus	23-33
25952969-11	2016	Consistent with its function as a WNT antagonist, SostAb treatment enhanced beta-catenin activity, but also increased the levels of SOST in the callus and in circulation.	sostab	50-56	sclerostin	Mus musculus	132-136
25836764-4	2015	This early activation at 1h appeared to be independent of receptor (Lrp5/6) mediated activation as it occurred in the presence of the inhibitors sclerostin and/or Dkk1.	Hydrogen	25-27	sclerostin	Mus musculus	145-155
25836764-5	2015	The COX-2 inhibitor, Carprofen, blocked the activation of beta-catenin signaling and decline in sclerostin positive osteocytes post-loading implying an important role for prostaglandin.	carprofen	21-30	sclerostin	Mus musculus	96-106
25660312-0	2015	Glutathione, N-acetylcysteine and lipoic acid down-regulate starvation-induced apoptosis, RANKL/OPG ratio and sclerostin in osteocytes: involvement of JNK and ERK1/2 signalling.	Glutathione	0-11	sclerostin	Mus musculus	110-120
25660312-0	2015	Glutathione, N-acetylcysteine and lipoic acid down-regulate starvation-induced apoptosis, RANKL/OPG ratio and sclerostin in osteocytes: involvement of JNK and ERK1/2 signalling.	Acetylcysteine	13-29	sclerostin	Mus musculus	110-120
25660312-0	2015	Glutathione, N-acetylcysteine and lipoic acid down-regulate starvation-induced apoptosis, RANKL/OPG ratio and sclerostin in osteocytes: involvement of JNK and ERK1/2 signalling.	Thioctic Acid	34-45	sclerostin	Mus musculus	110-120
25446885-0	2015	Alterations in vitamin D metabolite, parathyroid hormone and fibroblast growth factor-23 concentrations in sclerostin-deficient mice permit the maintenance of a high bone mass.	Vitamin D	15-24	sclerostin	Mus musculus	107-117
25446885-2	2015	We review the mechanisms by which Sost knockout mice are able to accrete increased amounts of calcium and phosphorus required for the maintenance of a high bone mass.	Calcium	94-101	sclerostin	Mus musculus	34-38
25446885-2	2015	We review the mechanisms by which Sost knockout mice are able to accrete increased amounts of calcium and phosphorus required for the maintenance of a high bone mass.	Phosphorus	106-116	sclerostin	Mus musculus	34-38
25255472-9	2015	CONCLUSIONS: Our observations suggest that spatial changes in the level and distribution of sclerostin in the alveolar LCS trigger successive bone remodelling due to orthodontic tooth movement.	lcs	119-122	sclerostin	Mus musculus	92-102
25044211-5	2014	Reduction of beta-catenin protein was concurrent with systemic elevation of LRP5/6 antagonists DKK1 and sclerostin in Pb-exposed mice throughout fracture healing.	Lead	118-120	sclerostin	Mus musculus	104-114
24876121-4	2014	Recent research suggests that other, heretofore unrecognized factors, such as the osteocyte-specific protein sclerostin, also regulate renal calcium excretion.	Calcium	141-148	sclerostin	Mus musculus	109-119
24876121-6	2014	Deletion of the sclerostin gene in mice significantly diminishes urinary calcium excretion and increases fractional renal calcium reabsorption.	Calcium	73-80	sclerostin	Mus musculus	16-26
24876121-6	2014	Deletion of the sclerostin gene in mice significantly diminishes urinary calcium excretion and increases fractional renal calcium reabsorption.	Calcium	122-129	sclerostin	Mus musculus	16-26
24876121-8	2014	Thus, evidence is accumulating that sclerostin directly or indirectly reduces renal calcium reabsorption, suggesting the presence of a novel calcium-excreting bone-kidney axis.	Calcium	84-91	sclerostin	Mus musculus	36-46
24876121-8	2014	Thus, evidence is accumulating that sclerostin directly or indirectly reduces renal calcium reabsorption, suggesting the presence of a novel calcium-excreting bone-kidney axis.	Calcium	141-148	sclerostin	Mus musculus	36-46
24357520-1	2014	Both blunted osteocytic production of the Wnt inhibitor sclerostin (Scl) and increased T-cell production of the Wnt ligand Wnt10b contribute to the bone anabolic activity of intermittent parathyroid hormone (iPTH) treatment.	ipth	208-212	sclerostin	Mus musculus	56-66
24780398-0	2014	Enhanced prostacyclin formation and Wnt signaling in sclerostin deficient osteocytes and bone.	Epoprostenol	9-21	sclerostin	Mus musculus	53-63
24780398-1	2014	We show that prostacyclin production is increased in bone and osteocytes from sclerostin (Sost) knockout mice which have greatly increased bone mass.	Epoprostenol	13-25	sclerostin	Mus musculus	78-88
24780398-1	2014	We show that prostacyclin production is increased in bone and osteocytes from sclerostin (Sost) knockout mice which have greatly increased bone mass.	Epoprostenol	13-25	sclerostin	Mus musculus	90-94
24780398-5	2014	Increased prostacyclin production by osteocytes from sclerostin deficient mice could potentially contribute to the increased bone formation seen in this condition.	Epoprostenol	10-22	sclerostin	Mus musculus	53-63
23530237-0	2013	Sclerostin alters serum vitamin D metabolite and fibroblast growth factor 23 concentrations and the urinary excretion of calcium.	Vitamin D	24-33	sclerostin	Mus musculus	0-10
23530237-5	2013	Eight-week-old, male sost KO mice had increased serum 1alpha,25-dihydroxyvitamin D, decreased 24,25-dihydroxyvitamin D, decreased intact fibroblast growth factor 23, and elevated inorganic phosphorus concentrations compared with age-matched WT mice.	1,25-dihydroxyvitamin D	54-82	sclerostin	Mus musculus	21-25
23530237-5	2013	Eight-week-old, male sost KO mice had increased serum 1alpha,25-dihydroxyvitamin D, decreased 24,25-dihydroxyvitamin D, decreased intact fibroblast growth factor 23, and elevated inorganic phosphorus concentrations compared with age-matched WT mice.	24,25-dihydroxyvitamin D	94-118	sclerostin	Mus musculus	21-25
23530237-5	2013	Eight-week-old, male sost KO mice had increased serum 1alpha,25-dihydroxyvitamin D, decreased 24,25-dihydroxyvitamin D, decreased intact fibroblast growth factor 23, and elevated inorganic phosphorus concentrations compared with age-matched WT mice.	inorganic phosphorus	179-199	sclerostin	Mus musculus	21-25
23530237-8	2013	Urinary calcium and renal fractional excretion of calcium were decreased in sost KO mice compared with WT mice.	Calcium	8-15	sclerostin	Mus musculus	76-80
23530237-8	2013	Urinary calcium and renal fractional excretion of calcium were decreased in sost KO mice compared with WT mice.	Calcium	50-57	sclerostin	Mus musculus	76-80
23530237-9	2013	Sost KO and WT mice had similar serum calcium and parathyroid hormone concentrations.	Calcium	38-45	sclerostin	Mus musculus	0-4
23357248-9	2013	Exendin-4 reduced the mRNA expression and protein production of SOST/sclerostin under normal or high-glucose conditions in MLO-Y4 cells.	Glucose	101-108	sclerostin	Mus musculus	64-68
23357248-9	2013	Exendin-4 reduced the mRNA expression and protein production of SOST/sclerostin under normal or high-glucose conditions in MLO-Y4 cells.	Glucose	101-108	sclerostin	Mus musculus	69-79
23530237-0	2013	Sclerostin alters serum vitamin D metabolite and fibroblast growth factor 23 concentrations and the urinary excretion of calcium.	Calcium	121-128	sclerostin	Mus musculus	0-10
23073571-8	2012	Several downstream targets of Osx during bone formation have been  identified, including Satb2, vitamin D receptor and vascular endothelial growth factor as well as Dkk1 and Sost.	osx	30-33	sclerostin	Mus musculus	174-178
22522029-6	2012	Alternatively, beta-TCP particles treatment for 24 h significantly increased the osteocytic marker SOST/sclerostin mRNA expression and the release of inflammatory cytokines including TNF-alpha and IL-1beta into the culture media, but decreased the mRNA expression of another osteocytic marker dentin matrix protein-1 (DMP-1).	beta-tricalcium phosphate	15-23	sclerostin	Mus musculus	104-114
22735261-6	2012	Bony sclerostin expression was stimulated by estrogen deficiency and it was reversed by estradiol supplementation.	Estradiol	88-97	sclerostin	Mus musculus	5-15
21735478-7	2011	Like late osteocytes, they develop a dendritic morphology and express SOST/sclerostin and fibroblast growth factor 23 (FGF-23), regulated by parathyroid hormone (PTH) and 1,25-dihydroxyvitamin D(3).	1,25-dihydroxyvitamin D	171-194	sclerostin	Mus musculus	70-74
22586496-7	2012	Consistent with a primary role for ECM mineralization in osteocyte formation, we also found that inhibition of ECM mineralization, by omitting phosphate or adding sodium pyrophosphate, a recognized inhibitor of hydroxyapatite formation, resulted in a 15-fold decrease in mineral deposition that was closely accompanied by lower expression of E11 and other osteocyte markers such as Dmp1, Cd44 and Sost whilst expression of osteoblast markers Ocn and Col1a increased.	sodium pyrophosphate	163-183	sclerostin	Mus musculus	397-401
21952235-4	2011	Using chromatin immunoprecipitation analysis, we reveal that Sirt1 directly and negatively regulates Sost gene expression by deacetylating histone 3 at lysine 9 at the Sost promoter.	Lysine	152-158	sclerostin	Mus musculus	101-105
21952235-4	2011	Using chromatin immunoprecipitation analysis, we reveal that Sirt1 directly and negatively regulates Sost gene expression by deacetylating histone 3 at lysine 9 at the Sost promoter.	Lysine	152-158	sclerostin	Mus musculus	168-172
22082363-3	2011	Here, we show that both sclerostin and DKK1 inhibit PTH-stimulated cAMP production.	Cyclic AMP	67-71	sclerostin	Mus musculus	24-34
21735478-7	2011	Like late osteocytes, they develop a dendritic morphology and express SOST/sclerostin and fibroblast growth factor 23 (FGF-23), regulated by parathyroid hormone (PTH) and 1,25-dihydroxyvitamin D(3).	1,25-dihydroxyvitamin D	171-194	sclerostin	Mus musculus	75-85
21484764-3	2011	This study was undertaken to characterize the effects of a monoclonal antibody to sclerostin (Scl-AbI) in mice exposed to dexamethasone (DEX).	scl-abi	94-101	sclerostin	Mus musculus	82-92
21484764-3	2011	This study was undertaken to characterize the effects of a monoclonal antibody to sclerostin (Scl-AbI) in mice exposed to dexamethasone (DEX).	Dexamethasone	122-135	sclerostin	Mus musculus	82-92
21484764-3	2011	This study was undertaken to characterize the effects of a monoclonal antibody to sclerostin (Scl-AbI) in mice exposed to dexamethasone (DEX).	Dexamethasone	137-140	sclerostin	Mus musculus	82-92
21652726-8	2011	Dual energy x-ray absorptiometry-derived measures of intermittent PTH (iPTH)-induced bone gain were impaired in Sost(-/-) mice.	ipth	71-75	sclerostin	Mus musculus	112-116
21652726-14	2011	iPTH-induced resorption of cortical bone might be overstimulated in Sost-deficient environments.	ipth	0-4	sclerostin	Mus musculus	68-72
21652726-11	2011	Continuous PTH (cPTH) infusion resulted in equal bone loss in Sost(+/+) and Sost(-/-) mice as measured by dual energy x-ray absorptiometry.	cpth	16-20	sclerostin	Mus musculus	62-66
18501188-11	2008	PTH inhibited SOST mRNA expression 91% in COX-2 KO MSC cultures compared to 67% in WT cultures.	pth	0-3	sclerostin	Mus musculus	14-18